<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Renal vein thrombosis in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Renal vein thrombosis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Renal vein thrombosis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jai Radhakrishnan, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brad H Rovin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1869102435"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Renal vein thrombosis (RVT) describes a condition in which thrombus forms in the renal veins or their branches. RVT is rare and occurs most commonly in adults with nephrotic syndrome and newborn infants with volume contraction or inherited thrombophilia. It may present acutely with associated symptoms (such as flank pain, hematuria, and/or acute kidney injury [AKI]) or may remain asymptomatic and undiagnosed until complicated by pulmonary embolism (PE) or discovered incidentally by imaging studies.</p><p>This topic will review the clinical features and treatment of RVT in adults. Overviews of the nephrotic syndrome and causes of venous thrombosis are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3084.html" rel="external">"Overview of heavy proteinuria and the nephrotic syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H2126497860"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>There is wide variability in the reported rate of RVT, probably related to the selection of patients for study (eg, degree of nephrotic syndrome, and symptomatic or asymptomatic thrombosis since RVT is often clinically silent or mistakenly attributed to another cause) and methods of detection (since the sensitivities of the available tests differ).</p><p>The prevalence of RVT in patients with the nephrotic syndrome ranges from 5 to over 60 percent [<a href="#rid1">1-5</a>]. In studies of consecutive or unselected patients without membranous nephropathy who underwent venography, the prevalence of RVT ranges from 10 to 50 percent, most frequently due to minimal change disease, membranoproliferative glomerulonephritis, and focal segmental glomerulosclerosis [<a href="#rid4">4</a>]. A higher prevalence has been noted in patients with membranous nephropathy (20 to 60 percent) [<a href="#rid4">4,6-10</a>]. In the largest available prospective series of 151 patients with nephrotic syndrome (mean serum albumin 2.1 to 2.4 g/dL [21 to 24 g/L] and protein excretion 5.0 to 5.8 g/day), RVT was detected in 33 patients overall (22 percent) and in 20 of 69 patients with membranous nephropathy (29 percent) [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome"</a>.)</p><p>Spontaneous RVT is rare in ambulatory individuals who are not nephrotic or without an underlying renal malignancy [<a href="#rid11">11,12</a>]. Among 218 patients who presented with RVT in a single-center study, 143 had a malignancy (111 with renal cell carcinoma) and 43 patients had the nephrotic syndrome [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/2983.html" rel="external">"Clinical manifestations, evaluation, and staging of renal cell carcinoma"</a>.)</p><p>Some reported additional causes include trauma (including kidney biopsy), oral contraceptives, hypovolemia (especially in infants), inherited procoagulant defects, or extrarenal compression of the renal vein [<a href="#rid11">11,13</a>]. These patients did not become nephrotic, which demonstrates the important point that nephrotic syndrome is a cause, not the result, of RVT. RVT has also been reported in patients with coronavirus disease 2019 (COVID-19) [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability"</a>.)</p><p class="headingAnchor" id="H93516999"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>RVT may be unilateral or bilateral and may extend into the inferior vena cava (IVC). Although RVT is more often chronic, acute RVT can occur and has a more dramatic presentation [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H3943693636"><span class="h2">Acute RVT</span><span class="headingEndMark"> — </span>Acute RVT is most often due to trauma, severe dehydration (especially in infants), or a generalized hypercoagulable state. It is an uncommon complication of the nephrotic syndrome [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a> and  <a class="medical medical_review" href="/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome"</a>.)</p><p>Acute RVT typically presents with symptoms of renal infarction, including flank pain, microscopic or gross hematuria, a marked elevation in serum lactate dehydrogenase (without change in transaminases), and an increase in renal size on radiographic study [<a href="#rid1">1</a>]. Bilateral RVT can present with acute kidney injury (AKI).</p><p>Significant proteinuria is a rare complication of acute RVT in patients without underlying nephrotic syndrome [<a href="#rid6">6,16</a>]. In a case report, a previously healthy individual with bilateral RVT presented acutely with lower abdominal and flank pain and proteinuria (2.3 g over 24 hours); both the thrombus and proteinuria disappeared after two courses of urokinase following intravenous (IV) heparin [<a href="#rid16">16</a>]. The kidney appeared normal on subsequent kidney biopsy.</p><p class="headingAnchor" id="H4198638901"><span class="h2">Chronic RVT</span><span class="headingEndMark"> — </span>RVT most often has an insidious onset and produces no symptoms referable to the kidney [<a href="#rid6">6,8,9</a>]. In such patients, a pulmonary embolus is usually the only clinical clue to the possible presence of RVT or other deep vein thrombosis (DVT). Abnormal ventilation-perfusion scans (V/Q scans) of the lungs indicative or suggestive of pulmonary emboli have been found in as many as 10 to 30 percent of patients with chronic RVT, most of whom are asymptomatic [<a href="#rid1">1,4,6-9,17,18</a>]. (See  <a class="medical medical_review" href="/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome", section on 'Pulmonary embolism'</a>.)</p><p>It has been suggested that a chronic RVT in patients with nephrotic syndrome may lead to increased proteinuria or progressively worsening kidney function. However, this has never been clearly documented [<a href="#rid8">8</a>]. Furthermore, in a case report of a patient with unilateral RVT and nephrotic syndrome due to membranous nephropathy, bilateral ureteral catheterization studies showed no difference in protein excretion or creatinine clearance between the two kidneys [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H4152842183"><span class="h1">SURVEILLANCE</span><span class="headingEndMark"> — </span>Routine surveillance for RVT is <strong>not</strong> recommended in patients with nephrotic syndrome, even in those at high risk for RVT (eg, membranous nephropathy associated with protein excretion above 10 g/day and/or a serum albumin concentration below 2 g/dL [20 g/L]) [<a href="#rid2">2</a>]. In addition, we do not screen nephrotic patients with worsening nephrotic syndrome or slowly rising serum creatinine. However, patients with nephrotic syndrome at high risk for thrombosis should be evaluated for possible prophylactic anticoagulation. (See  <a class="medical medical_review" href="/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome"</a>.)</p><p>Several considerations limit the value of routine surveillance for RVT in asymptomatic patients with nephrotic syndrome: The evaluation of RVT potentially exposes patients to radiation and intravenous contrast; a patient with a negative study may develop RVT at a later time, requiring sequential studies; and there are no data demonstrating a benefit to diagnosing occult disease [<a href="#rid2">2</a>]. However, the detection of occult disease should prompt a reevaluation of the risks and benefit of anticoagulation if the patient is not already receiving such therapy. (See  <a class="medical medical_review" href="/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome"</a>.)</p><p>It is also <strong>not</strong> particularly useful to evaluate for RVT in a patient who experiences an overt embolic event (such as a pulmonary embolus) for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>It cannot be proven that the pulmonary embolus originated in the renal veins, since a deep vein thrombosis (DVT) in the lower extremities may have coexisted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In situ pulmonary thrombosis (not an embolus) may occur in patients with severe nephrotic syndrome and profound hypoalbuminemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most important, a patient with nephrotic syndrome who has developed a thromboembolic event will be treated with anticoagulants whether or not an RVT is present.</p><p></p><p>Taking all of these factors into consideration, it is rarely necessary to image the renal veins for a thrombus in patients with the nephrotic syndrome. An important exception occurs in the rare patient suspected of having acute, complete RVT (eg, signs or symptoms of a renal infarct), which will be accompanied by acute kidney injury (AKI) if it is bilateral. (See <a class="local">'Evaluation and diagnosis'</a> below.)</p><p>A separate issue is whether chronic bilateral RVT might be a cause of a rising serum creatinine or increasing proteinuria and, if so, whether anticoagulation might be beneficial. There are no data to support this hypothesis [<a href="#rid8">8</a>]. Opinions of experts vary as to whether or not patients with marked and progressive nephrotic syndrome or a slowly rising serum creatinine should undergo an imaging procedure to screen for RVT.</p><p class="headingAnchor" id="H226659987"><span class="h1">EVALUATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>As previously stated, most RVT is insidious and asymptomatic, and the diagnosis is established by imaging as an incidental finding. (See <a class="local">'Chronic RVT'</a> above.)</p><p>However, a diagnosis of acute, complete RVT should be suspected in patients with nephrotic syndrome who present with one of more of the following findings:</p><p class="bulletIndent1"><span class="glyph">●</span>New onset of flank pain or generalized abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>New onset of gross hematuria</p><p class="bulletIndent1"><span class="glyph">●</span>New increase in serum creatinine that is otherwise unexplained</p><p></p><p>There are no specific laboratory tests to diagnose RVT. In patients who are suspected of having acute, complete RVT, imaging should be performed to confirm the diagnosis. Although the gold standard diagnostic test for RVT is selective renal venography  (<a class="graphic graphic_diagnosticimage graphicRef69262" href="/d/graphic/69262.html" rel="external">image 1</a>), less invasive procedures are typically used, including computed tomography (CT) angiography and magnetic resonance (MR) venography [<a href="#rid4">4,5,20-23</a>].</p><p>Our approach to the selection of imaging modality is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m<sup>2</sup>, CT angiography is the preferred initial exam. The sensitivity and specificity of CT angiography for detecting RVT are approximately 92 and 100 percent, respectively, when compared with selective renal venography [<a href="#rid5">5</a>]. If CT angiography cannot be performed (eg, in patients who cannot receive iodinated intravenous [IV] contrast) or is unavailable, gadolinium-enhanced MR venography is the second-line option for initial imaging. When compared with CT angiography as a reference standard, the sensitivity and specificity of MR venography for RVT detection are approximately 94 and 100 percent, respectively [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup> or with acute kidney injury (AKI), we avoid CT angiography since such patients may be at risk for contrast-induced nephropathy. We offer MR venography to the patient and discuss the potential risks and benefits of gadolinium contrast administration in patients with severe kidney function impairment. If the patient agrees to undergoing MR venography, group II gadolinium agents should be used, and group I agents should be avoided.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/113083.html" rel="external">"Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography", section on 'Patients with eGFR &lt;30'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Patients with eGFR &lt;30 mL/min/1.73 m2 or with acute kidney injury'</a>.)</p><p></p><p>We do <strong>not </strong>routinely use Doppler ultrasonography to diagnose RVT in the native kidneys in view of the lower sensitivity with this technique. However, Doppler ultrasonography may be the only option if neither CT angiography nor MR venography is available. In one small study of 12 patients with suspected acute RVT, the absence or reversal of diastolic flow in the renal vein on Doppler ultrasonography had a sensitivity and specificity of only 40 and 47 percent, respectively, for detecting RVT when compared with renal venography or MR imaging (without gadolinium) [<a href="#rid21">21</a>]. There are no studies comparing the diagnostic accuracy of Doppler ultrasonography with that of CT angiography or MR venography. Although Doppler ultrasonography should not be used to evaluate for RVT in native kidneys, it is the exam of choice to detect RVT in the kidney allograft of kidney transplant recipients. (See  <a class="medical medical_review" href="/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction", section on 'Vascular thrombosis'</a>.)</p><p class="headingAnchor" id="H3799158985"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Certain patients with the nephrotic syndrome may benefit from anticoagulation to prevent the development of thromboembolic events, including RVT. This issue is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome"</a> and  <a class="medical medical_review" href="/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome", section on 'Prevention of thromboembolism'</a>.)</p><p class="headingAnchor" id="H344145077"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H2676283790"><span class="h2">Patients with acute RVT</span><span class="headingEndMark"> — </span>Management of an acute RVT depends upon whether the patient presents with acute kidney injury (AKI). In general, patients without AKI can be treated with therapeutic anticoagulation (unless contraindicated), whereas those with AKI should undergo dissolution or removal of the thrombus with thrombolytic therapy with or without thrombectomy.</p><p class="headingAnchor" id="H3189787068"><span class="h3">Without acute kidney injury</span><span class="headingEndMark"> — </span>Patients with an acute RVT or RVT with an associated thromboembolic event (deep vein thrombosis [DVT] or pulmonary embolism [PE]) who present without AKI are treated the same as patients who have a DVT or PE. Treatment typically consists of anticoagulation, unless contraindicated  (<a class="graphic graphic_table graphicRef107527" href="/d/graphic/107527.html" rel="external">table 1</a>), initially with unfractionated or low-molecular-weight heparin and then <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid25">25,26</a>]. Some patients with nephrotic syndrome are partially resistant to heparin therapy due to severe antithrombin deficiency.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Heparin resistance/antithrombin deficiency'</a>.)</p><p></p><p><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> therapy is given for a minimum of 6 to 12 months. In patients with nephrotic syndrome, most experts feel that warfarin should be continued for as long as the patient remains nephrotic with a serum albumin concentration &lt;3 g/dL [<a href="#rid1">1,2</a>].</p><p>The goal international normalized ratio (INR) is 2.0 to 3.0. This level of anticoagulation is associated with a modest increase in risk of bleeding; a higher bleeding risk, compared with less intense therapy, is observed particularly among older adults.</p><p>There is a paucity of data on the use of oral and parenteral direct thrombin inhibitors (eg, <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="8765" href="/d/drug information/8765.html" rel="external">argatroban</a>) and factor Xa inhibitors (eg, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a>) in patients with nephrotic syndrome, and, in general, patients with impaired kidney function have been excluded from studies of these agents. In a retrospective study of 21 patients with nephrotic syndrome treated with direct oral anticoagulants (19 for thromboprophylaxis and 2 for thromboembolic events), none of the patients experienced thromboembolism and five patients experienced minor bleeding episodes [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Settings in which a heparin or vitamin K antagonist may be preferable'</a>.)</p><p>In patients who cannot receive therapeutic anticoagulation due to a contraindication, suprarenal inferior vena cava (IVC) filters have occasionally been used and are thought to be relatively safe [<a href="#rid28">28</a>]. It is unclear if patients with a documented RVT without PE and contraindications to anticoagulation should receive an IVC filter. (See  <a class="medical medical_review" href="/d/html/8212.html" rel="external">"Placement of vena cava filters and their complications"</a>.)</p><p class="headingAnchor" id="H2538544040"><span class="h3">With acute kidney injury</span><span class="headingEndMark"> — </span>In patients with an acute RVT or RVT with an associated thromboembolic event (DVT or PE) who present with AKI, we favor local thrombolytic therapy with or without catheter thrombectomy. A combined approach is preferred for patients with bilateral RVT, a solitary kidney or transplanted kidney, or a large thrombus burden. Patients should then be maintained on therapeutic anticoagulation [<a href="#rid15">15</a>], as discussed above for patients with acute RVT who do not have AKI (see <a class="local">'Without acute kidney injury'</a> above). Systemic fibrinolysis has been used in patients with RVT but carries the risk of bleeding, including intracranial bleeding, and is not recommended [<a href="#rid16">16,29-31</a>]. (See  <a class="medical medical_review" href="/d/html/55.html" rel="external">"Acute ST-elevation myocardial infarction: The use of fibrinolytic therapy", section on 'Complications'</a>.)</p><p>Successful outcomes have been reported using local thrombolytic therapy with or without extraction catheter thrombectomy in nephrotic patients with acute RVT [<a href="#rid32">32-35</a>]. The potential efficacy of this approach was illustrated in a report of six patients (five of whom had proteinuric kidney disease, but level of proteinuria or serum albumin was not reported) with acute RVT who had percutaneous catheter thrombectomy followed by local thrombolysis for a mean of 22 hours [<a href="#rid33">33</a>]. Renal venous flow was restored in all patients, and the mean serum creatinine declined postprocedure from 3.3 to 1.9 mg/dL (292 to 168 micromol/L). At two years, kidney function was stable, and there were no further episodes of RVT.</p><p>Surgical thrombectomy is rarely performed given the availability of less invasive interventions such as catheter-directed thrombolysis and catheter thrombectomy. However, surgery is an alternative option for the rare patient with acute bilateral RVT and AKI who cannot be treated with percutaneous thrombectomy and/or thrombolysis [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H2752757786"><span class="h2">Patients with chronic RVT</span><span class="headingEndMark"> — </span>Chronic (asymptomatic) RVT is detected in one of two ways: during screening, which we do not recommend, and during imaging for some other reason. (See <a class="local">'Chronic RVT'</a> above and <a class="local">'Surveillance'</a> above.)</p><p>Therapeutic anticoagulation should be provided to patients with an incidentally discovered RVT, unless contraindicated. The approach to therapeutic anticoagulation in these patients is the same as that in patients with acute RVT or nonrenal thromboembolism. (See <a class="local">'Without acute kidney injury'</a> above.)</p><p>There are no randomized trials or definitive observational studies that have evaluated the role of anticoagulation in patients with nephrotic syndrome who have an asymptomatic RVT, but case series report treating such patients [<a href="#rid6">6,8</a>]. Possible benefits include prevention of extension of the RVT (eg, to the IVC), DVT, or PE, while the major risk is bleeding [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H4166252777"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113663.html" rel="external">"Society guideline links: Superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism"</a>.)</p><p class="headingAnchor" id="H3866459647"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Renal vein thrombosis (RVT) describes a condition in which thrombus forms in the renal veins or their branches. RVT is rare and occurs most commonly in adults with nephrotic syndrome and newborn infants with volume contraction or inherited thrombophilia. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– The reported prevalence of RVT in patients with the nephrotic syndrome varies widely. Spontaneous RVT is rare in ambulatory individuals who are not nephrotic or without an underlying renal malignancy. Some reported additional causes of RVT include trauma (including kidney biopsy), oral contraceptives, hypovolemia (especially in infants), and inherited procoagulant disorders. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– Acute RVT typically presents with symptoms of renal infarction, including flank pain, microscopic or gross hematuria, a marked elevation in serum lactate dehydrogenase (without change in transaminases), and an increase in kidney size on radiographic study. Bilateral acute RVT can present with acute kidney injury (AKI). By contrast, chronic RVT most often has an insidious onset and produces no symptoms referable to the kidney. In such patients, a pulmonary embolus is usually the only clinical clue to the possible presence of RVT or other deep vein thrombosis (DVT). (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance </strong>– Routine surveillance for RVT is <strong>not</strong> recommended in patients with nephrotic syndrome, even in those at high risk for RVT (eg, membranous nephropathy associated with protein excretion above 10 g/day and/or a serum albumin concentration below 2 g/dL [20 g/L]). In addition, we do not screen nephrotic patients with worsening nephrotic syndrome or slowly rising serum creatinine. (See <a class="local">'Surveillance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis </strong>– A diagnosis of acute, complete RVT should be suspected in patients with nephrotic syndrome who present with new onset of flank pain or generalized abdominal pain, new onset of gross hematuria, or new increase in serum creatinine that is otherwise unexplained. There are no specific laboratory tests to diagnose RVT. In patients who are suspected of having acute, complete RVT, imaging should be performed to confirm the diagnosis. Although the gold standard diagnostic test for RVT is selective renal venography, less invasive procedures are typically used, including computed tomography (CT) angiography and magnetic resonance (MR) venography. (See <a class="local">'Evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute RVT </strong>– Management of an acute RVT depends upon whether the patient presents with AKI. In general, patients without AKI can be treated with therapeutic anticoagulation (unless contraindicated), whereas those with AKI should undergo dissolution or removal of the thrombus with thrombolytic therapy with or without thrombectomy.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients with an acute RVT or RVT with an associated thromboembolic event (DVT or pulmonary embolism [PE]) who present without AKI, we recommend therapeutic anticoagulation rather than no anticoagulation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Anticoagulation should be continued for as long as the patient remains nephrotic, for a minimum of 6 to 12 months. The goal international normalized ratio (INR) is 2 to 3. The role of direct oral anticoagulation in treating RVT has not been established. (See <a class="local">'Without acute kidney injury'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients with an acute RVT or RVT with an associated thromboembolic event (DVT or PE) who present with AKI, we suggest local thrombolytic therapy with or without catheter thrombectomy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Patients should then be maintained on therapeutic anticoagulation as is administered to patients with acute RVT who do not present with AKI. (See <a class="local">'With acute kidney injury'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic RVT </strong>– In patients with an incidentally discovered RVT, we suggest therapeutic anticoagulation rather than no anticoagulation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The approach to therapeutic anticoagulation in these patients is the same as that in patients with acute RVT or nonrenal thromboembolism. (See <a class="local">'Patients with chronic RVT'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int 1985; 28:429.</a></li><li><a class="nounderline abstract_t">Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int 1994; 46:287.</a></li><li><a class="nounderline abstract_t">Crew RJ, Radhakrishnan J, Appel G. Complications of the nephrotic syndrome and their treatment. Clin Nephrol 2004; 62:245.</a></li><li><a class="nounderline abstract_t">Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res 2006; 118:397.</a></li><li><a class="nounderline abstract_t">Wei LQ, Rong ZK, Gui L, Shan RD. CT diagnosis of renal vein thrombosis in nephrotic syndrome. J Comput Assist Tomogr 1991; 15:454.</a></li><li><a class="nounderline abstract_t">Llach F, Papper S, Massry SG. The clinical spectrum of renal vein thrombosis: acute and chronic. Am J Med 1980; 69:819.</a></li><li><a class="nounderline abstract_t">Chugh KS, Malik N, Uberoi HS, et al. Renal vein thrombosis in nephrotic syndrome--a prospective study and review. Postgrad Med J 1981; 57:566.</a></li><li><a class="nounderline abstract_t">Wagoner RD, Stanson AW, Holley KE, Winter CS. Renal vein thrombosis in idiopathic membranous glomerulopathy and nephrotic syndrome: incidence and significance. Kidney Int 1983; 23:368.</a></li><li><a class="nounderline abstract_t">Velasquez Forero F, Garcia Prugue N, Ruiz Morales N. Idiopathic nephrotic syndrome of the adult with asymptomatic thrombosis of the renal vein. Am J Nephrol 1988; 8:457.</a></li><li><a class="nounderline abstract_t">Liu YC, Wang HY, Pan JS. [Renal vein thrombosis in nephrotic syndrome--a prospective study of 54 cases]. Zhonghua Nei Ke Za Zhi 1989; 28:208.</a></li><li><a class="nounderline abstract_t">Zucchelli P. Renal vein thrombosis. Nephrol Dial Transplant 1992; 7 Suppl 1:105.</a></li><li><a class="nounderline abstract_t">Wysokinski WE, Gosk-Bierska I, Greene EL, et al. Clinical characteristics and long-term follow-up of patients with renal vein thrombosis. Am J Kidney Dis 2008; 51:224.</a></li><li><a class="nounderline abstract_t">Wolak T, Rogachev B, Tovbin D, et al. Renal vein thrombosis as a presenting symptom of multiple genetic pro-coagulant defects. Nephrol Dial Transplant 2005; 20:827.</a></li><li><a class="nounderline abstract_t">Mui LW, Lau JF, Lee HK. Thromboembolic complications of COVID-19. Emerg Radiol 2021; 28:423.</a></li><li><a class="nounderline abstract_t">Asghar M, Ahmed K, Shah SS, et al. Renal vein thrombosis. Eur J Vasc Endovasc Surg 2007; 34:217.</a></li><li><a class="nounderline abstract_t">Morrissey EC, McDonald BR, Rabetoy GM. Resolution of proteinuria secondary to bilateral renal vein thrombosis after treatment with systemic thrombolytic therapy. Am J Kidney Dis 1997; 29:615.</a></li><li><a class="nounderline abstract_t">Cherng SC, Huang WS, Wang YF, et al. The role of lung scintigraphy in the diagnosis of nephrotic syndrome with pulmonary embolism. Clin Nucl Med 2000; 25:167.</a></li><li><a class="nounderline abstract_t">Kuhlmann U, Steurer J, Bollinger A, et al. [Incidence and clinical significance of thromboses and thrombo-embolic complications in nephrotic syndrome patients]. Schweiz Med Wochenschr 1981; 111:1034.</a></li><li><a class="nounderline abstract_t">Kauffmann RH, de Graeff J, de la Rivière GB, van Es LA. Unilateral renal vein thrombosis and nephrotic syndrome. Report of a case with protein selectivity and antithrombin III clearance studies. Am J Med 1976; 60:1048.</a></li><li><a class="nounderline abstract_t">Avasthi PS, Greene ER, Scholler C, Fowler CR. Noninvasive diagnosis of renal vein thrombosis by ultrasonic echo-Doppler flowmetry. Kidney Int 1983; 23:882.</a></li><li><a class="nounderline abstract_t">Platt JF, Ellis JH, Rubin JM. Intrarenal arterial Doppler sonography in the detection of renal vein thrombosis of the native kidney. AJR Am J Roentgenol 1994; 162:1367.</a></li><li><a class="nounderline abstract_t">Rahmouni A, Jazaerli N, Radier C, et al. Evaluation of magnetic resonance imaging for the assessment of renal vein thrombosis in the nephrotic syndrome. Nephron 1994; 68:271.</a></li><li><a class="nounderline abstract_t">Tempany CM, Morton RA, Marshall FF. MRI of the renal veins: assessment of nonneoplastic venous thrombosis. J Comput Assist Tomogr 1992; 16:929.</a></li><li><a class="nounderline abstract_t">Zhang LJ, Wu X, Yang GF, et al. Three-dimensional contrast-enhanced magnetic resonance venography for detection of renal vein thrombosis: comparison with multidetector CT venography. Acta Radiol 2013; 54:1125.</a></li><li><a class="nounderline abstract_t">Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol 2007; 18:2221.</a></li><li><a class="nounderline abstract_t">Wu CH, Ko SF, Lee CH, et al. Successful outpatient treatment of renal vein thrombosis by low-molecular weight heparins in 3 patients with nephrotic syndrome. Clin Nephrol 2006; 65:433.</a></li><li><a class="nounderline abstract_t">Kelddal S, Hvas AM, Grove EL, Birn H. Safety and effectiveness of direct oral anticoagulants in patients with nephrotic syndrome: a report of 21 cases. BMC Nephrol 2022; 23:305.</a></li><li><a class="nounderline abstract_t">Greenfield LJ, Cho KJ, Proctor MC, et al. Late results of suprarenal Greenfield vena cava filter placement. Arch Surg 1992; 127:969.</a></li><li><a class="nounderline abstract_t">Markowitz GS, Brignol F, Burns ER, et al. Renal vein thrombosis treated with thrombolytic therapy: case report and brief review. Am J Kidney Dis 1995; 25:801.</a></li><li><a class="nounderline abstract_t">Laville M, Aguilera D, Maillet PJ, et al. The prognosis of renal vein thrombosis: a re-evaluation of 27 cases. Nephrol Dial Transplant 1988; 3:247.</a></li><li><a class="nounderline abstract_t">Burrow CR, Walker WG, Bell WR, Gatewood OB. Streptokinase salvage of renal function after renal vein thrombosis. Ann Intern Med 1984; 100:237.</a></li><li><a class="nounderline abstract_t">Lam KK, Lui CC. Successful treatment of acute inferior vena cava and unilateral renal vein thrombosis by local infusion of recombinant tissue plasminogen activator. Am J Kidney Dis 1998; 32:1075.</a></li><li><a class="nounderline abstract_t">Kim HS, Fine DM, Atta MG. Catheter-directed thrombectomy and thrombolysis for acute renal vein thrombosis. J Vasc Interv Radiol 2006; 17:815.</a></li><li><a class="nounderline abstract_t">Weger N, Stawicki SP, Roll G, et al. Bilateral renal vein thrombosis secondary to membraneous glomerulonephritis: successful treatment with thrombolytic therapy. Ann Vasc Surg 2006; 20:411.</a></li><li><a class="nounderline abstract_t">Jaar BG, Kim HS, Samaniego MD, et al. Percutaneous mechanical thrombectomy: a new approach in the treatment of acute renal-vein thrombosis. Nephrol Dial Transplant 2002; 17:1122.</a></li><li><a class="nounderline abstract_t">Duffy JL, Letteri J, Clinque T, et al. Renal vein thrombosis and the nephrotic syndrome. Report of two cases with successful treatment of one. Am J Med 1973; 54:663.</a></li></ol></div><div id="topicVersionRevision">Topic 119627 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3906225" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7967339" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Thrombosis and hemostasis in renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15524054" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Complications of the nephrotic syndrome and their treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15990160" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2026809" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : CT diagnosis of renal vein thrombosis in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7446547" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The clinical spectrum of renal vein thrombosis: acute and chronic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7329894" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Renal vein thrombosis in nephrotic syndrome--a prospective study and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6842962" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Renal vein thrombosis in idiopathic membranous glomerulopathy and nephrotic syndrome: incidence and significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3218659" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Idiopathic nephrotic syndrome of the adult with asymptomatic thrombosis of the renal vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2805956" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : [Renal vein thrombosis in nephrotic syndrome--a prospective study of 54 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1337175" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Renal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18215700" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical characteristics and long-term follow-up of patients with renal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741213" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Renal vein thrombosis as a presenting symptom of multiple genetic pro-coagulant defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33159219" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Thromboembolic complications of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17543556" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Renal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9100053" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Resolution of proteinuria secondary to bilateral renal vein thrombosis after treatment with systemic thrombolytic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10698409" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The role of lung scintigraphy in the diagnosis of nephrotic syndrome with pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7268357" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : [Incidence and clinical significance of thromboses and thrombo-embolic complications in nephrotic syndrome patients].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/937349" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Unilateral renal vein thrombosis and nephrotic syndrome. Report of a case with protein selectivity and antithrombin III clearance studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6224961" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Noninvasive diagnosis of renal vein thrombosis by ultrasonic echo-Doppler flowmetry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8192001" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Intrarenal arterial Doppler sonography in the detection of renal vein thrombosis of the native kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7830872" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evaluation of magnetic resonance imaging for the assessment of renal vein thrombosis in the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1430444" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : MRI of the renal veins: assessment of nonneoplastic venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23794130" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Three-dimensional contrast-enhanced magnetic resonance venography for detection of renal vein thrombosis: comparison with multidetector CT venography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17599972" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16792140" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Successful outpatient treatment of renal vein thrombosis by low-molecular weight heparins in 3 patients with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36064370" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Safety and effectiveness of direct oral anticoagulants in patients with nephrotic syndrome: a report of 21 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1642540" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Late results of suprarenal Greenfield vena cava filter placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7747736" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Renal vein thrombosis treated with thrombolytic therapy: case report and brief review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3140096" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The prognosis of renal vein thrombosis: a re-evaluation of 27 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6691668" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Streptokinase salvage of renal function after renal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9856527" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Successful treatment of acute inferior vena cava and unilateral renal vein thrombosis by local infusion of recombinant tissue plasminogen activator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16687747" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Catheter-directed thrombectomy and thrombolysis for acute renal vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16604403" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bilateral renal vein thrombosis secondary to membraneous glomerulonephritis: successful treatment with thrombolytic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12032209" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Percutaneous mechanical thrombectomy: a new approach in the treatment of acute renal-vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4701947" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Renal vein thrombosis and the nephrotic syndrome. Report of two cases with successful treatment of one.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
